Recursion Pharmaceuticals
clinical would be first in class inhibitor for treatment of appears well suited other inhibitors | Recursion Pharmaceuticals
Company
Deck Type
Sector
Industry
Deck date
January 2023
Slide
103 of 143
Related slides by other companies
MindMed
Investor Presentation
June 2023
business highlights a leader in developing product candidates to treat brain health disorders diversified pipeline of clinical programs targeting significant unmet medical needs and strategies intended to maximize market exclusivity and protection in drug and digital medicine development and commercialization expected cash runway through key clinical and into first half of tartrate for the treatment of gad and or for the treatment of core symptoms of | MindMed
Ocuphire Pharma
Results
October 2022
oral treatments in clinical development | Ocuphire Pharma
Alkermes
Investor Conference
January 2022
novel selective inhibitor candidate | Alkermes
Alkermes
Investor Day
March 2021
focus and discipline integral to portfolio advancement discovery phase enabling phase phase phase phase alfa intravenous dosing alfa subcutaneous dosing neurology orphan agonist inhibitors neurology neuropsychiatry non orphan inhibitors frontotemporal dementia tumor targeted split inhibitors oncology oncology | Alkermes
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io